Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae

(2019) James A. McKinnell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nephrotoxicity Associated with Intravenous Polymyxin B Once versus Twice Daily Dosing Regimen

(2018) Adeola Okoduwa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†

(2018) Peter M Hawkey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

(2018) Mical Paul et al.   LANCET INFECTIOUS DISEASES

Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study

(2018) Ritesh Aggarwal et al.   Annals of Clinical Microbiology and Antimicrobials

Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis

(2018) Amber Martin et al.   Open Forum Infectious Diseases

Prospective, comparative clinical study between high-dose colistin monotherapy and colistin–meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae

(2018) Mohamed Farouk Ahmed Abdelsalam et al.   Journal of Global Antimicrobial Resistance

Comparison of RIFLE, AKIN, and KDIGO classifications for assessing prognosis of patients on extracorporeal membrane oxygenation

(2017) Tsung-Yu Tsai et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

(2017) Bin Cai et al.   Open Forum Infectious Diseases

Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients

(2016) William R. Judd et al.   AMERICAN JOURNAL OF INFECTION CONTROL

The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study

(2016) Yael Dishon Benattar et al.   CLINICAL INFECTIOUS DISEASES

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study

(2015) Lidia Dalfino et al.   CLINICAL INFECTIOUS DISEASES

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?

(2015) Roger L. Nation et al.   CLINICAL INFECTIOUS DISEASES

High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia

(2015) Ali S Omrani et al.   Annals of Clinical Microbiology and Antimicrobials

In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy

(2014) K. Phe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

(2013) Emanuele Durante-Mangoni et al.   CLINICAL INFECTIOUS DISEASES

Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center

(2013) Darowan S. Akajagbor et al.   CLINICAL INFECTIOUS DISEASES

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

(2013) L Silvia Munoz-Price et al.   LANCET INFECTIOUS DISEASES

Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity—An Overview for Applied Toxicology

(2011) Tobias Christian Fuchs et al.   AAPS Journal

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

(2011) S. M. Garonzik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health System

(2011) J. M. Pogue et al.   CLINICAL INFECTIOUS DISEASES

The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic

(2010) L. S. Elias et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY